Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2011 1
2012 1
2013 1
2015 2
2016 1
2017 2
2018 1
2019 1
2020 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.
Hsu J, Donahue RN, Katragadda M, Lowry J, Huang W, Srinivasan K, Guntas G, Tang J, Servattalab R, Moisan J, Tsai YT, Stoop A, Palakurthi S, Chopra R, Liu K, Wherry EJ, Su Z, Gulley JL, Bayliffe A, Schlom J. Hsu J, et al. Among authors: bayliffe a. Sci Transl Med. 2023 Nov 29;15(724):eadi0258. doi: 10.1126/scitranslmed.adi0258. Epub 2023 Nov 29. Sci Transl Med. 2023. PMID: 38019931 Free PMC article.
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials.
Vantourout P, Eum J, Conde Poole M, Hayday TS, Laing AG, Hussain K, Nuamah R, Kannambath S, Moisan J, Stoop A, Battaglia S, Servattalab R, Hsu J, Bayliffe A, Katragadda M, Hayday AC. Vantourout P, et al. Among authors: bayliffe a. Sci Adv. 2023 Dec 8;9(49):eadj6174. doi: 10.1126/sciadv.adj6174. Epub 2023 Dec 6. Sci Adv. 2023. PMID: 38055824 Free PMC article.
The authors reply.
Christie J, Lazaar A, Bayliffe A. Christie J, et al. Among authors: bayliffe a. Crit Care Med. 2016 Jun;44(6):e454-5. doi: 10.1097/CCM.0000000000001790. Crit Care Med. 2016. PMID: 27182882 No abstract available.
Emerging therapeutic targets in psoriasis.
Bayliffe AI, Brigandi RA, Wilkins HJ, Levick MP. Bayliffe AI, et al. Curr Opin Pharmacol. 2004 Jun;4(3):306-10. doi: 10.1016/j.coph.2004.02.003. Curr Opin Pharmacol. 2004. PMID: 15140425 Review.
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.
Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL. Khan A, et al. Among authors: bayliffe ai. Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x. Crit Care. 2017. PMID: 28877748 Free PMC article. Clinical Trial.
Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury.
Proudfoot A, Bayliffe A, O'Kane CM, Wright T, Serone A, Bareille PJ, Brown V, Hamid UI, Chen Y, Wilson R, Cordy J, Morley P, de Wildt R, Elborn S, Hind M, Chilvers ER, Griffiths M, Summers C, McAuley DF. Proudfoot A, et al. Among authors: bayliffe a. Thorax. 2018 Aug;73(8):723-730. doi: 10.1136/thoraxjnl-2017-210305. Epub 2018 Jan 29. Thorax. 2018. PMID: 29382797 Free PMC article. Clinical Trial.
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension.
Simon MA, Hanrott K, Budd DC, Torres F, Grünig E, Escribano-Subias P, Meseguer ML, Halank M, Opitz C, Hall DA, Hewens D, Powley WM, Siederer S, Bayliffe A, Lazaar AL, Cahn A, Rosenkranz S. Simon MA, et al. Among authors: bayliffe a. Pulm Circ. 2022 Jan 20;12(1):e12024. doi: 10.1002/pul2.12024. eCollection 2022 Jan. Pulm Circ. 2022. PMID: 35506108 Free PMC article.
A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study.
Ryan J, Bayliffe AI, McAuley DF, Yeung J, Thickett DR, Howells PA, O'Donnell C, Vassallo AM, Wright TJ, McKie E, Hardes K, Summers C, Shields MO, Powley W, Wilson R, Lazaar AL, Fowler A, Perkins GD. Ryan J, et al. Among authors: bayliffe ai. Eur J Anaesthesiol. 2020 Nov;37(11):1014-1024. doi: 10.1097/EJA.0000000000001245. Eur J Anaesthesiol. 2020. PMID: 32467417 Free PMC article. Clinical Trial.
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
Christie JD, Vaslef S, Chang PK, May AK, Gunn SR, Yang S, Hardes K, Kahl L, Powley WM, Lipson DA, Bayliffe AI, Lazaar AL. Christie JD, et al. Among authors: bayliffe ai. Crit Care Med. 2015 Sep;43(9):1859-69. doi: 10.1097/CCM.0000000000001132. Crit Care Med. 2015. PMID: 26102252 Clinical Trial.
Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.
Cordy JC, Morley PJ, Wright TJ, Birchler MA, Lewis AP, Emmins R, Chen YZ, Powley WM, Bareille PJ, Wilson R, Tonkyn J, Bayliffe AI, Lazaar AL. Cordy JC, et al. Among authors: bayliffe ai. Clin Exp Immunol. 2015 Nov;182(2):139-48. doi: 10.1111/cei.12680. Epub 2015 Sep 11. Clin Exp Immunol. 2015. PMID: 26178412 Free PMC article. Clinical Trial.
16 results